A fiber-modified adenovirus co-expressing HSV-TK and coli. NTR enhances antitumor activities in breast cancer cells

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 2850-2860

  Zhan, Yang ^a   Yu, Bin ^a   Wang, Zhen ^a   Zhang, Yu ^a   Zhang, Hai Hong ^a   Wu, Hao ^a   Feng, Xiao ^a   Geng, Ran Shen ^a   Kong, Wei ^a   Yu, Xiang Hui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Adenovirus; Breast cancer; Suicide gene

Indexed keywords

ESCHERICHIA COLI PROTEIN; NFSA PROTEIN, E COLI; NITROREDUCTASE; THYMIDINE KINASE; VIRUS PROTEIN;

ADENOVIRIDAE; ANIMAL; BREAST TUMOR; DRUG SCREENING; ESCHERICHIA COLI; FEMALE; FLOW CYTOMETRY; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MOUSE; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMPLEXVIRUS; SUICIDE TRANSGENE; TUMOR CELL LINE; VIROLOGY;

ADENOVIRIDAE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; FLOW CYTOMETRY; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; NITROREDUCTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMPLEXVIRUS; THYMIDINE KINASE; VIRAL PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904252972     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
2. Both GW. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol Ther 2009; 11: 421-432.
3. Schellmann N, Deckert PM, Bachran D, Fuchs H and Bachran C. Targeted enzyme prodrug therapies. Mini Rev Med Chem 2010; 10: 887-904.
4. Vassaux G and Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin Biol Ther 2004; 4: 519-530.
5. Doloff JC and Waxman DJ. Adenoviral vectors for prodrug activation-based gene therapy for cancer. Anticancer Agents Med Chem 2014; 14: 115-126.
6. Sewell DA, Li D, Duan L, Schwartz MR and O'Malley BW Jr. Optimizing suicide gene therapy for head and neck cancer. Laryngoscope 1997; 107: 1490-1495.
7. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, Raben D and Curiel DT. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748.
8. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL and Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
9. Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, Crowell RL and Finberg RW. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J.Virol 1998; 72: 415-419.
10. Campos SK and Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007; 7: 189-204.
11. Sullivan DE, Dash S, Du H, Hiramatsu N, Aydin F, Kolls J, Blanchard J, Baskin G and Gerber MA. Liver-directed gene transfer in non-human primates. Hum Gene Ther 1997; 8: 1195-1206.
12. Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP and Curiel DT. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 2003; 63: 847-853.
13. Huard J, Lochmuller H, Acsadi G, Jani A, Massie B and Karpati G. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107-115.
14. Giaginis CT, Zarros AC, Papaefthymiou MA, Papadopouli AE, Sfiniadakis IK and Theocharis SE. Coxsackievirus and adenovirus receptor expression in human endometrial adenocarcinoma: possible clinical implications. World J Surg Oncol 2008; 6: 59.
15. Sachs MD, Rauen KA, Ramamurthy M, Dodson JL, De Marzo AM, Putzi MJ, Schoenberg MP and Rodriguez R. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology 2002; 60: 531-536.
16. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N and Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-1852.
17. Xia D, Henry LJ, Gerard RD and Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994; 2: 1259-1270.
18. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N and Curiel DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
19. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT and Hemminki A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
20. Kasono K, Blackwell JL, Douglas JT, Dmitriev I, Strong TV, Reynolds P, Kropf DA, Carroll WR, Peters GE, Bucy RP, Curiel DT and Krasnykh V. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999; 5: 2571-2579.
21. Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D and Curiel DT. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002; 62: 4273-4281.
22. Salama SA, Kamel M, Christman G, Wang HQ, Fouad HM and Al-Hendy A. Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecol Obstet Invest 2007; 63: 61-70.
23. Patterson AV, Saunders MP and Greco O. Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 2003; 9: 2131-2154.
24. Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, Harris PA, Mountain A and Wrighton CJ. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol Ther 2001; 3: 233-240.
25. Yu B, Zhang Y, Zhan Y, Zha X, Wu Y, Zhang X, Dong Q, Kong W and Yu X. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep 2011; 26: 255-264.
26. Sekar TV, Foygel K, Ilovich O and Paulmurugan R. Noninvasive Theranostic Imaging of HSV1-sr39TK-NTR/GCV-CB1954 Dual-Prodrug Therapy in Metastatic Lung Lesions of MDA-MB-231 Triple Negative Breast Cancer in Mice. Theranostics 2014; 4: 460-474.
27. Howitt J, Bewley MC, Graziano V, Flanagan JM and Freimuth P. Structural basis for variation in adenovirus affinity for the cellular coxsackievirus and adenovirus receptor. J Biol Chem 2003; 278: 26208-26215.
28. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996; 12: 697-715.
29. Wickham TJ, Mathias P, Cheresh DA and Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
30. Uckert W, Kammertons T, Haack K, Qin Z, Gebert J, Schendel DJ and Blankenstein T. Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo. Hum Gene Ther 1998; 9: 855-865.
31. Anders M, Rösch T, Küster K, Becker I, Höfler H, Stein HJ, Meining A, Wiedenmann B and Sarbia M. Expression and function of the coxsackie and adenovirus receptor in Barrett's esophagus and associated neoplasia. Cancer Gene Ther 2009; 16: 508-515.
32. Stecker K, Koschel A, Wiedenmann B and Anders M. Loss of Coxsackie and adenovirus receptor downregulates alpha-catenin expression. Br J Cancer 2009; 101: 1574-1579.
33. Wu PC, Wang Q, Dong ZM, Chu E, Roberson RS, Ivanova IC and Wu DY. Expression of coxsackie and adenovirus receptor distinguishes transitional cancer states in therapy-induced cellular senescence. Cell Death Dis 2010; 1: e70.
34. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F and Dammacco F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002; 87: 836-845.
35. Desgrosellier JS and Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
36. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM and Tjuvajev JG. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 2003; 21: 405-413.